Piotr Grabarczyk

Piotr Grabarczyk

Auto-generated profile, based on publicly available information

Piotr Grabarczyk

Clinic for Internal Medicine C, University Greifswald, 17489 Greifswald, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
PGPiotr Grabarczyk
Piotr Grabarczyk
PWPassorn Winkler
Passorn Winkler
MDMartin Delin
Martin Delin
PSPraveen K. Sappa
Praveen K. Sappa
Sander BekeschusSander Bekeschus
Sander Bekeschus
CSChristian A. Schmidt
Christian A. Schmidt
The BCL11B gene encodes a Krüppel-like, sequence-specific zinc finger transcription factor that acts as either a repressor or an activator, depending on its post-translational modifications. The importance of BCL11B in numerous biological processes in multiple organs has been well established in mouse knockout models. The phenotype of the first de novo monoallelic germline missense mutation in the BCL11B gene (N441K) strongly implies that the mutant protein acts in a dominant negative manner by neutralizing the unaffected protein through the formation of a nonfunctional dimer.

22 March 2011 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SNStefan Nagel
Stefan Nagel
LVLetizia Venturini
Letizia Venturini
GPGrzegorz Przybylski
Grzegorz Przybylski
PGPiotr Grabarczyk
Piotr Grabarczyk
BSBjörn Schneider
Björn Schneider
RMRoderick A. F. MacLeod
Roderick A. F. MacLeod
In T-cell acute lymphoblasic leukemia (T-ALL), neoplastic chromosomal rearrangements are known to deregulate members of the homeobox gene families NKL and HOXA. Here, analysis of T-ALL cell lines and primary cells identified aberrant expression of a third homeobox gene group, the Paired (PRD) class. LOUCY cells revealed chromosomal deletion at 5q31, which targets the downstream regulatory region of the PRD homeobox gene PITX1, removing a STAT1 binding site. STAT1 mediates repressive interleukin 2 (IL2)-STAT1 signaling, implicating IL2 pathway avoidance as a possible activation mechanism. Among primary T-ALL samples, 2/22 (9%) aberrantly expressed PITX1, highlighting the importance of this gene. Forced expression of PITX1 in JURKAT cells and subsequent target gene analysis prompted deregulation of genes involved in T-cell development including HES1, JUN, NKX3-1, RUNX1, RUNX2, and TRIB2. Taken together, our data show leukemic activation of PITX1, a novice PRD-class homeobox gene in a subset of early-staged T-ALL, which may promote leukemogenesis by inhibiting T-cell development.

15 May 2011 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
XHXin Huang
Xin Huang
QSQi Shen
Qi Shen
SCSi Chen
Si Chen
SCShaohua Chen
Shaohua Chen
LYLijian Yang
Lijian Yang
YLYangqiu Li
Yangqiu Li
Background: Downregulation of the B-cell chronic lymphocytic leukemia (CLL)/lymphoma11B (BCL11B) gene by small interfering RNA (siRNA) leads to growth inhibition and apoptosis of the human T-cell acute lymphoblastic leukemia (T-ALL) cell line Molt-4. To further characterize the molecular mechanism, a global gene expression profile of BCL11B-siRNA -treated Molt-4 cells was established. The expression profiles of several genes were further validated in the BCL11B-siRNA -treated Molt-4 cells and primary T-ALL cells. Results: 142 genes were found to be upregulated and 109 genes downregulated in the BCL11B-siRNA -treated Molt-4 cells by microarray analysis. Among apoptosis-related genes, three pro-apoptotic genes, TNFSF 10, BIK, BNIP 3, were upregulated and one anti-apoptotic gene, BCL2L 1 was downregulated. Moreover, the expression of SPP 1 and CREBBP genes involved in the transforming growth factor (TGF-β) pathway was down 16-fold. Expression levels of TNFSF 10, BCL2L 1, SPP 1, and CREBBP were also examined by real-time PCR. A similar expression pattern of TNFSF 10, BCL2L 1, and SPP 1 was identified. However, CREBBP was not downregulated in the BLC11B-siRNA -treated Molt-4 cells. Conclusion: BCL11B-siRNA treatment altered expression profiles of TNFSF 10, BCL2L 1, and SPP 1 in both Molt-4 T cell line and primary T-ALL cells.

1 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FBFloriane C M Braun
Floriane C M Braun
JBJens Van Den Brandt
Jens Van Den Brandt
STSören Thomas
Sören Thomas
SLSandra Lange
Sandra Lange
JSJuliane Schrank
Juliane Schrank
PGPiotr Grabarczyk
Piotr Grabarczyk
A20 is an ubiquitin-editing enzyme that ensures the transient nature of inflammatory signaling pathways induced by cytokines like TNF-α and IL-1 or pathogens via Toll-like receptor (TLR) pathways. It has been identified as a negative regulator of dendritic cell (DC) maturation and attenuator of their immunostimulatory properties. Ex vivo A20-depleted dendritic cells showed enhanced expression of pro-inflammatory cytokines and costimulatory molecules, which resulted in hyperactivation of tumor-infiltrating T lymphocytes and inhibition of regulatory T cells. In the present study, we demonstrate that a synthetic molecule consisting of a CpG oligonucleotide TLR9 agonist linked to A20-specific siRNAs silences its expression in TLR9+ mouse dendritic cells in vitro and in vivo. In the B16 mouse melanoma tumor model, silencing of A20 enhances the CpG-triggered induction of NFκB activity followed by elevated expression of IL-6, TNF-α and IL-12. This leads to potentiated antitumor immune responses manifested by increased numbers of tumor-specific cytotoxic T cells, high levels of tumor cell apoptosis and delayed tumor growth. Our findings confirm the central role of A20 in controlling the immunostimulatory potency of DCs and provide a strategy for simultaneous A20 silencing and TLR activation in vivo.

30 June 2002 in Acta Biochimica Polonica
Verified
Journal Article
Open access
PDF file
PGPiotr Grabarczyk
Piotr Grabarczyk
PWPiotr J Wysocki
Piotr J Wysocki
KGKatarzyna Gryska
Katarzyna Gryska
AMAndrzej Mackiewicz
Andrzej Mackiewicz
Recombinant retroviral vectors are still the most common gene delivery vehicles for gene therapy purposes, especially for construction of genetically modified tumor vaccines (GMTV). However, these vehicles are characterized by relatively low titre and in the case of many tumor cell lines, low transduction efficiency. We constructed bicistronic retroviral vector pseudotypes of amphotropic murine leukemia virus (A-MuLV) and gibbon ape leukemia virus (GaLV), encoding enhanced green fluorescent protein (EGFP) as a rapid and easily detectable reporter gene. Transduction of five different human melanoma and four renal carcinoma cell lines by these two virus pseudotypes revealed differences in transduction efficiency, which wase markedly lower for the renal carcinoma cell lines. Stimulation of retroviral receptor expression (PiT1 and PiT2) by phosphate depletion induced a limited increase of receptor mRNA levels, but did not improve the gene transfer efficiency. In contrast, simultaneous transduction with both vector pseudotypes markedly increased the transduction efficiency, compared to GaLV or A-MuLV alone. The same effect could be achieved by several repeated exposures of target cells to fresh vector preparation. Overexpression of GaLV receptor (PiT1) in target cells significantly increased the transduction rate and enabled retrovirus mediated gene transfer into the cells which normally are not transducible by GaLV pseudotypes. We demonstrated that, using different transduction strategies, the relatively inefficient, widely used retroviral vector systems could be significantly improved.

9 April 2014 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Katarzyna IżykowskaKatarzyna Iżykowska
Katarzyna Iżykowska
MZMariola Zawada
Mariola Zawada
KNKarina Nowicka
Karina Nowicka
PGPiotr Grabarczyk
Piotr Grabarczyk
AKAndreas W. Kuss
Andreas W. Kuss
GPGrzegorz K. Przybylski
Grzegorz K. Przybylski